Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 243 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Male Participants Clear all

Conditions: Females, Males, Menopause, Sedentary, Healthy Participants
Interventions: Vitamin C (Ascorbic Acid); Dietary Supplement
Lead sponsor: University of Virginia; Other
Eligibility: 45 Years and older
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Healthy Participants
Interventions: Quemliclustat; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Renal Impairment, Healthy
Interventions: PF-07328948; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Lake Forest, California • Orlando, Florida • Tampa, Florida + 1 more

Conditions: Healthy
Interventions: Nirogacestat, Nirogacestat and Famotidine, Nirogacestat and Rabeprazole; Drug
Lead sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Respiratory Syncytial Virus Infections
Interventions: 200 mg RV521/78 µCi [ 14C]-RV521.; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Fatigue Syndrome, Fibromyalgia, Gulf War Illness, Multiple Chemical Sensitivity, Interstitial Cystitis, Irritable Bowel Syndrome
Interventions: Not listed
Lead sponsor: Georgetown University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Healthy Participants
Interventions: BMS-986165, MMF; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy
Interventions: JNJ-42756493; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 30 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Participants
Interventions: JZP047, Placebo; Drug · Other
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Renal Impairment
Interventions: AZD5004; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Miami Lakes, Florida • Orlando, Florida

Conditions: Healthy
Interventions: JNJ-54452840, Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 20 Years to 55 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy Volunteers
Interventions: 14C-labeled ASP0367; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions: VX-407, Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Chronic Kidney Disease
Interventions: OJR520, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: [¹⁴C]-LY4515100 Oral Solution, LY4515100 Tablet, [¹⁴C]-LY4515100 IV; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Participants
Interventions: INCB123667; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Dilated Cardiomyopathy
Interventions: AZD0233, AZD0233 Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Dyslipidemia
Interventions: AZD0780, Ezetimibe, Rosuvastatin, Bempedoic Acid, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Clear Cell Renal Cell Carcinoma (ccRCC)
Interventions: BMS-986527, Nivolumab, Cabozantinib; Drug
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 6
States / cities: New Haven, Connecticut • Basking Ridge, New Jersey • New York, New York + 3 more

Conditions: Healthy Male Volunteers
Interventions: Oral [14C] PF-07799544, Oral Unlabeled PF-07799544, IV [14C] PF-07799544; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: BMS-986460; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Renal Impairment
Interventions: Tavapadon; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Jacksonville, Florida • Miami, Florida • Tampa, Florida

Conditions: Hematological Malignancy
Interventions: Nemtabrutinib; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Weight Loss, Gut Microbiome, Anti-Aging
Interventions: P-IF, HH; Behavioral
Lead sponsor: Skidmore College; Other
Eligibility: 25 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Saratoga Springs, New York

Search by objective public record fields.

The Effects of Vitamin C on Acute-Exercise in Postmenopausal Females

Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function

Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat

A Study to Learn About Effect of Sisunatovir in Healthy Adult Male Participants

Proteomics of Cerebrospinal Fluid in Chronic Fatigue Syndrome

An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants

A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male Participants

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants

A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004

To Assess the Pharmacokinetics and Safety of Single Doses of JNJ-54452840 in Healthy Japanese and Caucasian Participants

A Study to Learn How [14C]ASP0367 is Processed by the Body in Healthy Men

A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease

A Study of LY4515100 in Healthy Male Participants

Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.

A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.

A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)

A Study to Understand What the Body Does to the Study Medicine Called PF-07799544 When Taken by Healthy Adults

A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants

To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function

A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)

Low Sugar Protein Pacing, Intermittent Fasting Diet in Men and Women